News

Sep 07, 2021 Atossa Therapeutics Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Additional Time to Vote

Sep 02, 2021 Atossa Therapeutics Receives Approval from the Swedish Ethics Review Authority to Initiate a Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density in Sweden

Aug 13, 2021 Atossa Therapeutics Announces Second Quarter 2021 Financial Results - Provides Corporate Update and Information about Upcoming Stockholder Meeting

Aug 05, 2021 Atossa Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9-10, 2021

Jul 07, 2021 Atossa Therapeutics Receives Regulatory Approval To Open Clinical Study of AT-H201 in Australia

Jun 16, 2021 Atossa Therapeutics Set to Be Included in the Russell 2000 and Russell 3000 Indexes

Jun 11, 2021 Atossa Therapeutics Receives Approval from Swedish Regulators to Initiate Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density

Jun 09, 2021 Atossa Therapeutics Announces Final Data from Phase 2 Endoxifen Breast Cancer Study Primary Endpoint Met: 65.1% Reduction in Biomarker Ki-67; Secondary Endpoint Met: Endoxifen Safe and Well Tolerated

Jun 07, 2021 Atossa Therapeutics to Release Final Data from Phase 2 Study of Endoxifen Administered to Breast Cancer Patients Prior to Surgery at a Webinar at 8 am Pacific Time on June 9, 2021

May 14, 2021 Atossa Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate Update

<< < > >>